AU2008215659B2 - Pharmaceutical composition comprising microparticle oily suspension - Google Patents

Pharmaceutical composition comprising microparticle oily suspension

Info

Publication number
AU2008215659B2
AU2008215659B2 AU2008215659A AU2008215659A AU2008215659B2 AU 2008215659 B2 AU2008215659 B2 AU 2008215659B2 AU 2008215659 A AU2008215659 A AU 2008215659A AU 2008215659 A AU2008215659 A AU 2008215659A AU 2008215659 B2 AU2008215659 B2 AU 2008215659B2
Authority
AU
Australia
Prior art keywords
active ingredient
medicinally
particle diameter
pharmaceutical composition
mean particle
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2008215659A
Other languages
English (en)
Other versions
AU2008215659A1 (en
Inventor
Yasunori Sato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aska Pharmaceutical Co Ltd
Original Assignee
Aska Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aska Pharmaceutical Co Ltd filed Critical Aska Pharmaceutical Co Ltd
Publication of AU2008215659A1 publication Critical patent/AU2008215659A1/en
Application granted granted Critical
Publication of AU2008215659B2 publication Critical patent/AU2008215659B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2008215659A 2007-02-16 2008-02-15 Pharmaceutical composition comprising microparticle oily suspension Active AU2008215659B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007-035916 2007-02-16
JP2007035916 2007-02-16
PCT/JP2008/000230 WO2008099615A1 (ja) 2007-02-16 2008-02-15 微粒子油性懸濁液を含む医薬組成物

Publications (2)

Publication Number Publication Date
AU2008215659A1 AU2008215659A1 (en) 2008-08-21
AU2008215659B2 true AU2008215659B2 (en) 2012-11-01

Family

ID=39689861

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008215659A Active AU2008215659B2 (en) 2007-02-16 2008-02-15 Pharmaceutical composition comprising microparticle oily suspension

Country Status (9)

Country Link
US (1) US8309138B2 (https=)
EP (1) EP2123255B1 (https=)
JP (2) JP4588791B2 (https=)
KR (1) KR101434706B1 (https=)
CN (1) CN101610754A (https=)
AU (1) AU2008215659B2 (https=)
CA (1) CA2677842C (https=)
ES (1) ES2423929T3 (https=)
WO (1) WO2008099615A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101814186B1 (ko) 2008-09-17 2018-03-14 키아스마 인코포레이티드 약제학적 조성물 및 연관된 투여방법
CN103655512B (zh) * 2013-12-12 2015-05-20 海南海力制药有限公司 一种硝酸芬替康唑阴道软胶囊及其制备方法
WO2016126830A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
WO2019022152A1 (ja) 2017-07-26 2019-01-31 学校法人同志社 ＴＧＦ－βシグナルに起因する障害を治療または予防するための医薬およびその応用
WO2019036663A1 (en) * 2017-08-17 2019-02-21 University Of Delaware FURANE COMPOSITIONS AND METHODS OF MAKING THE SAME
BR112020006677A2 (pt) 2017-10-05 2020-10-06 Fulcrum Therapeutics, Inc. uso de inibidores p38 para reduzir a expressão de dux4
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025772A1 (en) * 1998-10-30 2000-05-11 F. Hoffmann-La Roche Ag Compositions of and process for producing isotretinoin having low particle size
WO2000038652A1 (en) * 1998-12-23 2000-07-06 Amgen Inc. Polyol/oil suspensions for the sustained release of proteins
WO2002015903A2 (de) * 2000-08-24 2002-02-28 Schwarz Pharma Ag Neue pharmazeutische zusammensetzung zur verabreichung von n-0923
JP2005112753A (ja) * 2003-10-06 2005-04-28 Sankyo:Kk 生物学的利用能を向上させたソフトカプセル
WO2005105052A1 (en) * 2004-05-04 2005-11-10 Hormos Medical Ltd. Novel oral formulations of ospemifene
WO2006070927A1 (ja) * 2004-12-28 2006-07-06 Aska Pharmaceutical Co., Ltd. ピリミジニルイソオキサゾール誘導体
JP2007039408A (ja) * 2005-08-05 2007-02-15 Unitec Foods Co Ltd 微粉化クレアチンとその製造方法

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8546591A (en) * 1990-09-13 1992-04-15 Smithkline Beecham Corporation Non-aqueous liquid oral suspensions
MX9300141A (es) 1992-01-13 1994-07-29 Smithkline Beecham Corp Compuestos de imidazol novedosos, procedimiento para su preparacion y composiciones farmaceuticas que lo contienen.
JPH0616556A (ja) 1992-07-02 1994-01-25 Yoshitomi Pharmaceut Ind Ltd 難溶性薬物含有製剤
US5651983A (en) * 1993-02-26 1997-07-29 The Procter & Gamble Company Bisacodyl dosage form for colonic delivery
US5656290A (en) * 1993-02-26 1997-08-12 The Procter & Gamble Company Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery
JPH07138151A (ja) 1993-11-15 1995-05-30 Kanebo Ltd ソフトカプセル剤及びその製造方法
BR9607035A (pt) 1995-02-13 1997-11-04 Searle & Co Isoxazois substituidos para o tratamento de inflamação
JPH1081621A (ja) 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
WO1998007414A1 (en) 1996-08-22 1998-02-26 Research Triangle Pharmaceuticals Ltd. Compositions comprising microparticles of water-insoluble substances and method for preparing same
US5736151A (en) 1996-12-09 1998-04-07 Pharmacia & Upjohn Company Antibiotic oil suspensions
AU754830C (en) 1997-05-22 2004-02-12 G.D. Searle Llc Substituted pyrazoles as p38 kinase inhibitors
CA2320087C (en) * 1998-02-09 2006-12-19 Joel Bolonick Treatment of chronic inflammatory disorders of the gastrointestinal tract
JPH11302156A (ja) 1998-04-16 1999-11-02 Tanabe Seiyaku Co Ltd ポリペプチドの微粒子化方法
JP4191825B2 (ja) 1998-09-10 2008-12-03 あすか製薬株式会社 ５−アミノイソキサゾール誘導体
KR100711538B1 (ko) 1998-12-25 2007-04-27 아스카 세이야쿠 가부시키가이샤 아미노피라졸 유도체
WO2000040220A1 (en) * 1999-01-06 2000-07-13 Korea Research Institute Of Chemical Technology Method of preparing pharmaceutical active ingredient comprising water-insoluble drug and pharmaceutical composition for oral administration comprising the same
BR0008403A (pt) 1999-02-23 2002-01-29 Merck & Co Inc Formulação farmacêutica para administração oral
DE60033028T2 (de) 1999-04-23 2007-11-15 Takeda Pharmaceutical Co. Ltd. 5-pyridyl-1,3-azol-derivate, verfahren zu ihrer herstellung und ihre verwendung
ATE284205T1 (de) 1999-10-01 2004-12-15 Natco Pharma Ltd Magensaftresistente gelartige weichkapsel
IN192188B (https=) 2000-06-16 2004-03-13 Ranbaxy Lab Ltd
AU2001289438A1 (en) * 2000-09-22 2002-04-02 Galephar M/F Pharmaceutical semi-solid composition of isotretinoin
PL371133A1 (en) 2001-12-20 2005-06-13 Pharmacia Corporation Pharmaceutical suspension for oral administration
EP1490025B1 (en) 2002-03-20 2008-02-13 Elan Pharma International Limited Nanoparticulate compositions of map kinase inhibitors
GB0214268D0 (en) 2002-06-20 2002-07-31 Celltech R&D Ltd Chemical compounds
AU2003251661A1 (en) 2002-08-06 2004-02-25 F. Hoffmann-La Roche Ag 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
TW200412948A (en) 2002-08-23 2004-08-01 Ionix Pharmaceuticals Ltd Therapeutic compounds
JP2004099442A (ja) 2002-09-04 2004-04-02 Nisshin Pharma Inc 難溶性薬物含有製剤およびその製造方法
EP1546141A1 (en) 2002-09-06 2005-06-29 Vertex Pharmaceuticals Incorporated Isoxazoles and their use in the treatment of ischemic diseases
MXPA05006670A (es) 2002-12-18 2005-10-19 Algorx Pharmaceuticals Inc Administracion de capsaicinoides.
US7550480B2 (en) 2003-02-14 2009-06-23 Smithkline Beecham Corporation Compounds
EP1601672B1 (en) 2003-02-14 2006-07-26 Pfizer Products Inc. Triazolo-pyridines as anti-inflammatory compounds
JPWO2004073692A1 (ja) 2003-02-18 2006-06-01 山下　伸二 難水溶性薬物のハードカプセル剤
JP2005013938A (ja) 2003-06-27 2005-01-20 Canon Inc 脱色装置及び方法
US20060151899A1 (en) 2003-08-06 2006-07-13 Akira Kato Process for producing drug ultramicroparticle and apparatus therefor
GB0402143D0 (en) 2004-01-30 2004-03-03 Smithkline Beecham Corp Novel compounds
WO2005085249A1 (en) 2004-02-27 2005-09-15 F. Hoffmann-La Roche Ag Fused derivatives of pyrazole

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000025772A1 (en) * 1998-10-30 2000-05-11 F. Hoffmann-La Roche Ag Compositions of and process for producing isotretinoin having low particle size
WO2000038652A1 (en) * 1998-12-23 2000-07-06 Amgen Inc. Polyol/oil suspensions for the sustained release of proteins
WO2002015903A2 (de) * 2000-08-24 2002-02-28 Schwarz Pharma Ag Neue pharmazeutische zusammensetzung zur verabreichung von n-0923
JP2005112753A (ja) * 2003-10-06 2005-04-28 Sankyo:Kk 生物学的利用能を向上させたソフトカプセル
WO2005105052A1 (en) * 2004-05-04 2005-11-10 Hormos Medical Ltd. Novel oral formulations of ospemifene
WO2006070927A1 (ja) * 2004-12-28 2006-07-06 Aska Pharmaceutical Co., Ltd. ピリミジニルイソオキサゾール誘導体
JP2007039408A (ja) * 2005-08-05 2007-02-15 Unitec Foods Co Ltd 微粉化クレアチンとその製造方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAMAMOTO H et al. Drug Delivery System. 2002. 17(4): 321-329 *

Also Published As

Publication number Publication date
KR20090117894A (ko) 2009-11-13
WO2008099615A1 (ja) 2008-08-21
US20100092565A1 (en) 2010-04-15
EP2123255A4 (en) 2010-06-02
JPWO2008099615A1 (ja) 2010-05-27
EP2123255B1 (en) 2013-05-15
JP2010120974A (ja) 2010-06-03
US8309138B2 (en) 2012-11-13
CN101610754A (zh) 2009-12-23
AU2008215659A1 (en) 2008-08-21
CA2677842C (en) 2014-09-16
JP4588791B2 (ja) 2010-12-01
EP2123255A1 (en) 2009-11-25
CA2677842A1 (en) 2008-08-21
KR101434706B1 (ko) 2014-08-26
ES2423929T3 (es) 2013-09-25

Similar Documents

Publication Publication Date Title
AU2008215659B2 (en) Pharmaceutical composition comprising microparticle oily suspension
EP2018158B1 (fr) Nouvelle forme d'administration du racecadotril
CA2903440C (en) Solid compositions comprising a glucokinase activator and methods of making and using the same
TW200821298A (en) Pharmaceutical compositions
JP2011157390A (ja) 胃液において不溶性の微小顆粒、その調製方法、および薬学的調製物
CN109803684B (zh) 用于治疗肝细胞癌的组合疗法
JP5021887B2 (ja) アゼチジン誘導体に基づく医薬組成物
JP2015510947A (ja) 小分子ｇｌｐ１ｒアゴニストのトリス（ヒドロキシメチル）アミノメタン塩ならびにその医薬組成物および使用
EP0981340A1 (fr) Formulations pharmaceutiques presentees sous forme seche pour l'administration orale d'un compose ammonium quaternaire cyclique
JPWO2006073154A1 (ja) 医薬組成物及びその製造方法
JP2008543723A (ja) ロシグリタゾンを含む経口製剤
KR100980752B1 (ko) 담체 표면 상에 흡착된 페노피브레이트를 포함하는 과립 및 이를 포함하는 약학 조성물
RU2476208C2 (ru) Стабильная фармацевтическая композиция водорастворимой соли винорелбина
TWI597063B (zh) 藥物組成物及其製備方法
JP2007504190A (ja) ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンズイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−エチルプロピオネート及びそれらの塩の新規経口投与形態
TWI746418B (zh) 包含1-[6-(嗎啉-4-基)嘧啶-4-基]-4-(1h-1,2,3-三唑-1-基)-1h-吡唑-5-醇鈉之醫藥劑型
JP7847966B2 (ja) 医薬製剤およびその製造方法
JP5106119B2 (ja) シクロオキシゲナーゼ−２阻害剤を含む経口投与用の薬剤、およびその調製方法
KR100980749B1 (ko) 페노피브레이트-함유 과립 및 이를 포함하는 약학 조성물
CA3187241A1 (en) Pharmaceutical compositions comprising ribociclib
MX2007002871A (es) Composicion farmaceutica de liberacion prolongada de hidralazina y su uso como apoyo para el tratamiento de cancer.
HK1070840B (en) Pharmaceutical compositions based on azetidine derivatives

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE INVENTION TITLE TO READ PHARMACEUTICAL COMPOSITION COMPRISING MICROPARTICLE OILY SUSPENSION

FGA Letters patent sealed or granted (standard patent)